Spago Nanomedical approved Peter Wulff as nominated to the board of directors at the annual general meeting replacing Jörgen Buus Lassen who has declined re-election. Peter Wulff currently acts as independent biotechnology consultant with focus on patents, licensing and strategy, and has extensive experience of managerial and board positions in different life science companies. He recently co-founded and served as CEO of Sentinext Tehrapeutics in Malaysia.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.244 SEK | -7.92% | -9.29% | -25.38% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-25.38% | 5.13M | |
-31.06% | 9.41B | |
-8.43% | 3.03B | |
+27.31% | 2.9B | |
-14.31% | 2.16B | |
-18.94% | 1.7B | |
+73.13% | 1.51B | |
+30.25% | 814M | |
-1.97% | 760M | |
-26.73% | 529M |
- Stock Market
- Equities
- SPAG Stock
- News Spago Nanomedical AB
- Spago Nanomedical Approves Appointment of Peter Wulff to its Board of Directors Replacing Jörgen Buus Lassen